日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death

Runx3 的强制表达通过增强对活化诱导细胞死亡的抵抗力提高了 CAR-T 细胞在实体肿瘤中的效力

Yi Wang, Honghong Zhang, Guoxiu Du, Hong Luo, Jingwen Su, Yansha Sun, Min Zhou, Bizhi Shi, Henry Q X Li, Hua Jiang, Zonghai Li

Phase II study of DFP-10917, a deoxycytidine analog, given by 14-day continuous intravenous infusion for chemotherapy-refractory advanced colorectal cancer

DFP-10917(一种脱氧胞苷类似物)的II期研究,采用14天持续静脉输注的方式治疗化疗难治性晚期结直肠癌。

Mehrvarz Sarshekeh, Amir; Xiong, Henry Q; Iizuka, Kenzo; Hochster, Howard S; Kopetz, Scott

A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial

吉西他滨联合白蛋白紫杉醇加阿帕托森或安慰剂治疗转移性胰腺癌患者的随机、双盲、II期临床试验:RAINIER试验

Ko, Andrew H; Murphy, Patrick B; Peyton, James D; Shipley, Dianna L; Al-Hazzouri, Ahmed; Rodriguez, Francisco A; Womack, Mark S 4th; Xiong, Henry Q; Waterhouse, David M; Tempero, Margaret A; Guo, Shuangli; Lane, Cassie M; Earwood, Chris; DeBusk, Laura M; Bendell, Johanna C

Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

随机概念验证 II 期试验,比较基于肿瘤分子分析的靶向治疗与难治性癌症患者的常规治疗:SHIVA 试验可行性部分的结果

C Le Tourneau, X Paoletti, N Servant, I Bièche, D Gentien, T Rio Frio, A Vincent-Salomon, V Servois, J Romejon, O Mariani, V Bernard, P Huppe, G Pierron, F Mulot, C Callens, J Wong, C Mauborgne, E Rouleau, C Reyes, E Henry, Q Leroy, P Gestraud, P La Rosa, L Escalup, E Mitry, O Trédan, J-P Delord, M

Patterns of self-reported symptoms in pancreatic cancer patients receiving chemoradiation

接受放化疗的胰腺癌患者的自我报告症状模式

Reyes-Gibby, Cielito C; Chan, Wenyaw; Abbruzzese, James L; Xiong, Henry Q; Ho, Linus; Evans, Douglas B; Varadhachary, Gauri; Bhat, Samrat; Wolff, Robert A; Crane, Christopher